Blow To Roche Growth Prospects As TIGIT Lung Cancer Trial Fails
Cancer Combination Fails In Phase III
Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.
You may also be interested in...
Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.
Drug makers have sought to branch into new frontiers of drug development in areas like cancers and neurology, but not all of them have been success stories. Here, Scrip looks at some of the more notable clinical trial misses of last year.
Arcus and Gilead’s latest Phase II readout has produced mixed signals, but some analysts are reassured about the potential of domvanalimab and the wider TIGIT field.